| Title |
Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, October 2014
|
| DOI | 10.2147/ndt.s68297 |
| Pubmed ID | |
| Authors |
Tariq Munshi, Usman Adam, Nusrat Husain, Peter Haddad, Fauzia Tariq, Farooq Naeem, Imran Chaudhry |
| Abstract |
Tardive dyskinesia (TD) is a side effect of antipsychotic treatment that often only appears after months or years of treatment. A systematic review of randomized controlled trials lasting more than 1 year showed that second-generation antipsychotics (SGAs) were associated with an approximately fivefold lower risk of TD compared to haloperidol in patients with chronic schizophrenia. In contrast, there is little research on the risk of TD with other first-generation antipsychotics (FGAs), and this applies especially to their use in the treatment of patients with first episode psychosis (FEP). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 3% |
| Unknown | 39 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 20% |
| Other | 5 | 13% |
| Researcher | 5 | 13% |
| Student > Doctoral Student | 4 | 10% |
| Professor > Associate Professor | 3 | 8% |
| Other | 8 | 20% |
| Unknown | 7 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 40% |
| Psychology | 8 | 20% |
| Nursing and Health Professions | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 4 | 10% |
| Unknown | 8 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2014.
All research outputs
#20,242,136
of 22,769,322 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,424
of 2,982 outputs
Outputs of similar age
#211,930
of 253,593 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#49
of 59 outputs
Altmetric has tracked 22,769,322 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,982 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,593 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.